Elias Kouchakji, MD

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen provides details of the phase 3 LELANTOS trial of pamrevlumab in Duchenne muscular dystrophy.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why the representation of non-ambulatory patient populations is necessary in DMD trials.

The senior vice president of clinical development, drug safety, and pharmacovigilance at FibroGen discussed why turning Duchenne muscular dystrophy into a chronic disease rather than a fatal one, is a top priority.